Interestingly, in light of these reports and together with our observations, PLVAP-targeting iatreusis is likely to supplement present therapeutic tactics for glioma, whether administered singly or in combination with immunotherapies, and it could also be used in the context of anti-angiogenesis therapeutics. Here, PLVAP is linked to central nervous system cancer.